AFP and hepatocellular carcinoma: For HCC patients at CNLC stage Ia, the sensitivity (95% CI) of AFP was 36.23% (25.26%, 48.75%), and the sensitivity (95% CI) of tRF‐3a‐Pro was 68.12% (55.67%, 78.53%) (Figure 3E).